Profile
| Metric | Value |
|---|---|
| Full Name | Arbutus Biopharma Corporation |
| Ticker | NASDAQ: ABUS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | arbutusbio.com |
| Employees | 44 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $4.62 | |
| Price, 1D Change | -0.65% | |
| Market Cap | $889M | |
| - | ||
| PE Ratio | - | |
| Beta | 0.87 | |
| Revenue | $6M | |
| Revenue, 1Y Change | -65.98% | |
| EPS | -$0.38 | |
| EPS, 1Y Change | +14.17% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:5 | |
| Next Split | N/A | N/A |
| Last Ticker Change | TKMR | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.38 | |
| EPS Estimate | -$0.26 | |
| EPS Est. Change | +31.25% | |
| Revenue | $6.17M | |
| Revenue Estimate | $19.13M | |
| Revenue Est. Change | +209.95% | |
| Current Price | $4.62 | |
| Price Target | - | $5.04 |
| Price Tgt. Change | - | +9.06% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.45 | -$0.44 | +2.47% | |
| -$0.55 | -$0.38 | +31.82% | |
| -$0.26 | N/A | +31.25% | |
| -$0.23 | N/A | +39.08% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $20.79M | $18.14M | -12.74% | |
| $8.72M | $6.17M | -29.26% | |
| $19.13M | N/A | +209.95% | |
| $2.64M | N/A | -57.23% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +37.91% | |
| Price, 3Y | +73.03% | |
| Market Cap, 1Y | +39.62% | |
| Market Cap, 3Y | +111.35% | |
| Revenue, 1Y | -65.98% | |
| Revenue, 3Y | -43.84% | |
| EPS, 1Y | +14.17% | |
| EPS, 3Y | +54.72% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $4.62 | |
| SMA 200 | $3.85 | |
| SMA 200 vs Price | -16.59% | |
| SMA 50 | $4.57 | |
| SMA 50 vs Price | -1.09% | |
| Beta | 0.87 | |
| ATR | $0.23 | |
| 14-Day RSI | 48.96 | |
| 10-Day Volatility | 38.60% | |
| 1-Year Volatility | 44.66% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $6.17M | |
| EPS | -$0.38 | |
| Gross Profit | $4.79M | |
| Gross Margin | 77.64% | |
| Operating Profit | -$69.97M | |
| Operating Margin | -1,133.92% | |
| Net Income | -$69.92M | |
| Net Margin | -1,133.04% | |
| EBITDA | -$68.59M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.06 | |
| 8.15 | ||
| 8.15 | ||
| - | ||
| 4 | ||
| 0.52 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 60.83 | ||
| 11.48 | ||
| -26.07 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $97.37M | |
| $122.62M | ||
| $131.71M | ||
| $127.32M | ||
| $34.34M | ||
| $15.62M | ||
| Total Debt | $6.12M | |
| $483.00K | ||
| $2.32M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $76.09M | ||
| $74.77M | ||
| $1.38M | ||
| $0.00 | ||
| $1.38M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$64.85M | ||
| $22.95M | ||
| $52.00M | ||
| Capex | $182.00K | |
| -$65.03M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Chardan Capital | → | |
| Chardan Capital | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Chardan Capital | → | |
| Jefferies | → | |
| JMP Securities | → |
Analyst sentiment
Institutional ownership
Screeners with ABUS
Data Sources & References
- ABUS Official Website www.arbutusbio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1447028/000144702825000126/0001447028-25-000126-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1447028/000144702825000083/0001447028-25-000083-index.htm
- ABUS Profile on Yahoo Finance finance.yahoo.com/quote/ABUS
- ABUS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/abus
FAQ
What is the ticker symbol for Arbutus Biopharma Corporation?
The ticker symbol for Arbutus Biopharma Corporation is NASDAQ:ABUS
Does Arbutus Biopharma Corporation pay dividends?
No, Arbutus Biopharma Corporation does not pay dividends
What sector is Arbutus Biopharma Corporation in?
Arbutus Biopharma Corporation is in the Healthcare sector
What industry is Arbutus Biopharma Corporation in?
Arbutus Biopharma Corporation is in the Biotechnology industry
What country is Arbutus Biopharma Corporation based in?
Arbutus Biopharma Corporation is headquartered in United States
When did Arbutus Biopharma Corporation go public?
Arbutus Biopharma Corporation initial public offering (IPO) was on July 26, 2007
Is Arbutus Biopharma Corporation in the S&P 500?
No, Arbutus Biopharma Corporation is not included in the S&P 500 index
Is Arbutus Biopharma Corporation in the NASDAQ 100?
No, Arbutus Biopharma Corporation is not included in the NASDAQ 100 index
Is Arbutus Biopharma Corporation in the Dow Jones?
No, Arbutus Biopharma Corporation is not included in the Dow Jones index
When was Arbutus Biopharma Corporation last earnings report?
Arbutus Biopharma Corporation's most recent earnings report was on November 13, 2025
When does Arbutus Biopharma Corporation report earnings?
The next expected earnings date for Arbutus Biopharma Corporation is March 26, 2026